Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
Thought Leadership
May 29, 2025

‘First published on Lexology’ By: Sandhya Singh, Sampada Kapoor and Kritika Gandhi Trademarks play a pivotal role in distinguishing the goods or services

Heir of the Family Trademarks
Thought Leadership
May 15, 2025

‘First published on India Business Law Journal’ By: Pravin Anand, Dr. Ajai Garg and Alvin Antony The ascendancy of large language models (LLMs) has

Navigating the AI frontier: India’s sovereign LLM quest
Thought Leadership
Apr 30, 2025

‘First published on Asia IP’ By: Prachi Agarwal and Manan Mondal In a significant ruling, the Division Bench of the Delhi High Court in Wipro Enterprises

Senior user versus junior user: Delhi High Court confirms passing off in a trademark dispute
Thought Leadership
Apr 29, 2025

‘First published on IP Stars’ By: Safir Anand, Omesh Puri and Abhishek Paliwal As the world changes and technology grows fast, the way we think about

The future of trademarks: shaping tomorrow’s brand identity